CompletedPhase 4ACTRN12610000034033

Intensive versus Conventional Therapy to Slow the Progression of Idiopathic Glomerular Diseases

Intensive versus Conventional Therapy on proteinuria and renal function in patients diagnosed with Glomerular Diseases

Sponsor

ASL6 Spedali Riuniti Livorno

Enrollment

130 participants

Start Date

Jan 1, 2003

Study Type

Interventional

Conditions

progression renal disease due to Idiopathic Glomerular Diseases

Summary

The main purpose of this study was to compare effects on proteinuria and renal function of two different therapeutic regimens: The first, was based on intensive therapy, which comprised a combination of renin angiotensin system inhibitors (Angiotensin converting enzyme inhibitors plus angiotensin receptor blocker spironolactone) and a dose of statin to achieve a low density lipoprotein ( LDL) cholesterol target less than 100 mg /dl. The second regimen (representative of a more conventional therapy) was based only on an angiotensin convertin enzyme inhibitors plus a dose of statin to achieve a low density lipoprotein ( LDL) cholesterol target less than 130 mg/dl

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares intensive versus standard treatment to slow kidney disease progression in people with a type of chronic kidney inflammation called glomerulonephritis. It is for adults aged 18 to 80 who have significant protein in their urine and adequate kidney function.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

We have studied two group of patients comparing intensive treatment versus standard treatment : In the intensive treatment group we used a combination of several drug including: Angiotensin convertin

We have studied two group of patients comparing intensive treatment versus standard treatment : In the intensive treatment group we used a combination of several drug including: Angiotensin converting enzyme inhibitor, (Ramipril;oral capsules dose- range 5-10 mg daily for 36 months prescribed by physician based on clinical variables) and Angiotensin receptor blocker (Irbesartan oral capsules: dose-range 150-300 mg daily for 36 months, prescribed by physician based on clinical variables ) to achieve a blood pressure goal of less than 130 /80 mm/Hg; Atorvastatin oral capsules (dose-range 20-40 mg daily for 36 months, prescribed by physician based on clinical variables ) to achieve low density lipoprotein ( LDL) cholesterol level less than 100 mg/dl; spironolactone, oral capsules (dose-range 25-50 mg daily, for 36 months,prescribed by physician based on clinical variables ) titrated to maintain serum potassium level less than 5.5 mEq/l. Patients in this group receive all 4 drugs on a daily basis.

Locations(1)

Livorno, Italy

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000034033